Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity

British Journal of Pharmacology

Volumn 173, Issue 11, 2016, Pages 1778-1792

  Scott, F L ^a   Clemons, B ^a   Brooks, J ^a   Brahmachary, E ^a   Powell, R ^a   Dedman, H ^a   Desale, H G ^a   Timony, G A ^a   Martinborough, E ^a   Rosen, H ^b   Roberts, E ^b   Boehm, M F ^a   Peach, R J ^a  

^a Receptos   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; CHEMOKINE RECEPTOR CCR7; CYCLOSPORIN; FINGOLIMOD; OZANIMOD; PREDNISOLONE; SIPONIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR 5; UNCLASSIFIED DRUG; INDAN DERIVATIVE; MOG PROTEIN, MOUSE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; OXADIAZOLE DERIVATIVE; TRINITROBENZENESULFONIC ACID;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; EXPERIMENTAL ALLERGIC ENCEPHALITIS; FEMALE; HEK293 CELL LINE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; T LYMPHOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRINITROBENZENE SULFONIC ACID-INDUCED COLITIS; VOLUME OF DISTRIBUTION; AGONISTS; ANIMAL; AUTOIMMUNE DISEASES; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; SCID MOUSE; SPRAGUE DAWLEY RAT;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; FEMALE; INDANS; INFLAMMATORY BOWEL DISEASES; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; OXADIAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LYSOSPHINGOLIPID; TRINITROBENZENESULFONIC ACID;

EID: 84966429005     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13476     Document Type: Article

References (61)

1. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015a). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744-5869.
2. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979-6023.
3. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024-6109.
4. Allende ML, Yamashita T, Proia RL, (2003). G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 102: 3665-3667.
5. Balatoni B, Storch MK, Swoboda EM, Schonborn V, Koziel A, Lambrou GN, et al., (2007). FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 74: 307-316.
6. Barkhof F, de Jong R, Sfikas N, de Vera A, Francis G, Cohen J, (2014). The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler 20: 1704-1713.
7. Brinkmann V, (2007). Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115: 84-105.
8. Brown P, (2009). Gilenya™ (Fingolimod HCl) Pharmacology Review(s).
9. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, et al., (2011). FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 108: 751-756.
10. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C, (2007). The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 323: 626-635.
11. Cohen J, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, et al., (2014). Phase 2 results of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis. Mult scler J 20: 497-500.
12. Croft M, Benedict CA, Ware CF, (2013). Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 12: 147-168.
13. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA, et al., (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461-3471.
14. Danese S, Panes J, (2014). Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases. Gastroenterology 147: 981-989.
15. Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke HH, Stein JM, (2007). FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4 + CD25+ regulatory T cells. J Immunol 178: 2458-2468.
16. Davenport RJ, Munday JR, (2007). Alpha4-integrin antagonism-an effective approach for the treatment of inflammatory diseases? Drug Discov Today 12: 569-576.
17. Deguchi Y, Andoh A, Yagi Y, Bamba S, Inatomi O, Tsujikawa T, et al., (2006). The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. Oncol Rep 16: 699-703.
18. Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, et al., (2008). Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 117: 77-93.
19. Fryer RM, Muthukumarana A, Harrison PC, Nodop Mazurek S, Chen RR, Harrington KE, et al., (2012). The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P(1)) and hypertension (S1P(3)) in rat. PLoS One 7.e52985.
20. Fujii R, Kanai T, Nemoto Y, Makita S, Oshima S, Okamoto R, et al., (2006). FTY720 suppresses CD4 + CD44highCD62L- effector memory T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol 291: G267-G274.
21. Galicia-Rosas G, Pikor N, Schwartz JA, Rojas O, Jian A, Summers-Deluca L, et al., (2012). A sphingosine-1-phosphate receptor 1-directed agonist reduces central nervous system inflammation in a plasmacytoid dendritic cell-dependent manner. J Immunol 189: 3700-3706.
22. Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, et al., (2012). The selective S1P receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate: translation from preclinical to clinical studies. Br J Pharmacol 167: 1035-1047.
23. Gonzalez-Cabrera PJ, Cahalan SM, Nguyen N, Sarkisyan G, Leaf NB, Cameron MD, et al., (2012). S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis. Mol Pharmacol 81: 166-174.
24. Gonzalez-Cabrera PJ, Jo E, Sanna MG, Brown S, Leaf N, Marsolais D, et al., (2008). Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like head-group interactions. Mol Pharmacol 74: 1308-1318.
25. Groves A, Kihara Y, Chun J, (2013). Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 328: 9-18.
26. Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH, (2010). Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke 41: 368-374.
27. Idzko M, Hammad H, van Nimwegen M, Kool M, Muller T, Soullie T, et al., (2006). Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 116: 2935-2944.
28. Jo E, Sanna MG, Gonzalez-Cabrera PJ, Thangada S, Tigyi G, Osborne DA, et al., (2005). S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 12: 703-715.
29. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, et al., (2005). FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2: 439-448.
30. Keller CD, Rivera Gil P, Tolle M, van der Giet M, Chun J, Radeke HH, et al., (2007). Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. Am J Pathol 170: 281-292.
31. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010) NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
32. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G, (2004). Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol 57: 586-591.
33. Krosser S, Wolna P, Fischer TZ, Boschert U, Stoltz R, Zhou M, et al., (2015). Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind placebo-controlled trial with an open-label fingolimod arm. J Clin Pharmacol 55: 1051-1060.
34. Lindebo Holm T, Poulsen SS, Markholst H, Reedtz-Runge S, (2012). Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease. Int J Inflam 2012: 412178.
35. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, et al., (2000). Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106: 951-961.
36. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al., (2002). Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349.
37. Martin R, Sospedra M, (2014). Sphingosine-1 phosphate and central nervous system. Curr Top Microbiol Immunol 378: 149-170.
38. Maxwell JR, Brown WA, Smith CL, Byrne FR, Viney JL, (2009). Methods of inducing inflammatory bowel disease in mice. Curr Protoc Pharmacol Chapter 5: Unit5 58. doi: 10.1002/0471141755.ph0558s47
39. McGrath JC, Lilley E, (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189-3193.
40. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, et al., (2008). FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71: 1261-1267.
41. Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P, et al., (2006). Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 34: 1480-1487.
42. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP, (2008). FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 63: 61-71.
43. Mizushima T, Ito T, Kishi D, Kai Y, Tamagawa H, Nezu R, et al., (2004). Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm Bowel Dis 10: 182-192.
44. Mullershausen F, Craveiro LM, Shin Y, Cortes-Cros M, Bassilana F, Osinde M, et al., (2007). Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem 102: 1151-1161.
45. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K, (2009). Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 5: 428-434.
46. Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, et al., (2002). Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol 29: 707-716.
47. Olsson T, Boster A, Fernandez O, Freedman MS, Pozzilli C, Bach D, et al., (2014). Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry 85: 1198-1208.
48. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, et al., (2007). Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282: 9082-9089.
49. Osinde M, Mullershausen F, Dev KK, (2007). Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 52: 1210-1218.
50. Ostanin DV, Pavlick KP, Bharwani S, D'Souza D, Furr KL, Brown CM, et al., (2006). T cell-induced inflammation of the small and large intestine in immunodeficient mice. Am J Physiol Gastrointest Liver Physiol 290: G109-G119.
51. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., NC-IUPHAR(2014). The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42: D1098-D1106.
52. Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG, (2008). S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 28: 122-133.
53. Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, et al., (2013). Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 12: 756-767.
54. Siarey R, (2009). Gilenya (Fingolimod HCL) Pharmacology/Toxicology NDA Review and Evaluation.
55. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER, (2009). The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 330: 864-875.
56. Song J, Matsuda C, Kai Y, Nishida T, Nakajima K, Mizushima T, et al., (2008). A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J Pharmacol Exp Ther 324: 276-283.
57. Thangada S, Khanna KM, Blaho VA, Oo ML, Im DS, Guo C, et al., (2010). Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med 207: 1475-1483.
58. Vaclavkova A, Chimenti S, Arenberger P, Hollo P, Sator PG, Burcklen M, et al., (2014). Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 384: 2036-2045.
59. van Doorn R, Nijland PG, Dekker N, Witte ME, Lopes-Pinheiro MA, van het Hof B, et al., (2012). Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol 124: 397-410.
60. Wang F, Tan W, Guo D, He S, (2007). Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720. Eur J Pharmacol 573: 230-240.
61. Xin C, Ren S, Eberhardt W, Pfeilschifter J, Huwiler A, (2006). The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br J Pharmacol 147: 164-174.